ipilimumab

ipilimumab
Fvasconcellos (talk · contribs) · Public domain · source
Drug name	Ipilimumab
Tradename	Yervoy
Dailymedid	Ipilimumab
Routes of administration	Intravenous
Drug class	Immune checkpoint inhibitor
Atc prefix	L01
Atc suffix	XC11
Legal status	Prescription only

ipilimumab Ipilimumab is a monoclonal antibody used in oncology that enhances immune responses against tumors. It is indicated for several malignancies and has been central to modern immunotherapy developments involving multiple institutions and regulatory agencies. Major clinical research programs and oncology consortia have evaluated its efficacy alongside surgical centers and pharmaceutical companies.

Medical uses

Ipilimumab is approved for treatment of unresectable or metastatic melanoma by regulatory bodies such as the Food and Drug Administration, the European Medicines Agency, and national agencies in Canada and Australia, and has been evaluated in combination with agents investigated by research groups at institutions like Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, and MD Anderson Cancer Center. It is also used in combination regimens for advanced non‑small cell lung cancer studied in trials with collaborators including University of California, Los Angeles, Massachusetts General Hospital, and industry partners such as Bristol Myers Squibb. Additional indications include adjuvant therapy after surgical resection assessed in multicenter networks including the European Organisation for Research and Treatment of Cancer and cooperative groups like the Alliance for Clinical Trials in Oncology. Ongoing investigations explore use in urothelial carcinoma, renal cell carcinoma, and colorectal cancer within consortia involving Johns Hopkins University and international cooperative trials coordinated by organizations such as SWOG.

Mechanism of action

Ipilimumab binds to cytotoxic T‑lymphocyte–associated protein 4 and blocks its inhibitory signaling, a mechanism elucidated in basic science labs affiliated with universities such as Stanford University, Harvard University, and University of Pennsylvania. By antagonizing this checkpoint, it augments T cell activation and proliferation observed in translational studies at centers including Fred Hutchinson Cancer Center and Sloan Kettering Institute, and in preclinical models developed in research groups led by investigators associated with the National Institutes of Health and biotech firms. The immune modulation results in antitumor activity that has been measured in correlative studies performed by pathology departments at institutions like Royal Marsden Hospital and immunology laboratories at University College London.

Dosage and administration

Ipilimumab is administered intravenously in oncology infusion centers affiliated with hospitals such as Cleveland Clinic, Karolinska University Hospital, and Guy's and St Thomas' NHS Foundation Trust. Standard dosing schedules evaluated in pivotal trials conducted by cooperative groups including EORTC and industry sponsors often used 3 mg/kg every 3 weeks for four doses for melanoma, while higher or weight‑based regimens and combination schedules with nivolumab were studied at centers like Vanderbilt University Medical Center and University of Texas MD Anderson Cancer Center. Pre‑medication, infusion duration, and monitoring protocols were developed in clinical pharmacology units at institutions such as Mayo Clinic and Royal Free Hospital.

Adverse effects

Immune‑related adverse events associated with ipilimumab—colitis, dermatitis, hepatitis, endocrinopathies—were characterized in case series from tertiary centers including Mount Sinai Hospital, Hospital Clínic de Barcelona, and Karolinska University Hospital, and management guidelines were produced by professional societies such as the American Society of Clinical Oncology and European Society for Medical Oncology. Severe events requiring corticosteroid or immunosuppressive therapy were reported in clinical trial sites organized by sponsors like Bristol Myers Squibb and monitored by institutional review boards at universities including Yale University and Columbia University. Rare fatal toxicities prompted alerts and risk‑management strategies coordinated with regulators like the FDA and national health ministries.

Pharmacology

Pharmacokinetic and pharmacodynamic profiles were defined in phase I and II studies run by academic units at University of California, San Francisco and industry research divisions at Bristol Myers Squibb. Ipilimumab displays nonlinear elimination at low concentrations and a terminal half‑life studied in laboratories at Queen Mary University of London and University of Toronto. Drug interaction potential and impact on concomitant therapies were examined in oncology pharmacology cores at Imperial College London and University of Washington, and immunogenicity assessments were performed in specialized labs such as those at Pasteur Institute.

Clinical trials and approvals

Pivotal randomized controlled trials leading to approval involved multicenter collaborations across cancer centers including Royal Marsden Hospital, Memorial Sloan Kettering Cancer Center, and Institut Gustave Roussy, sponsored by pharmaceutical companies and monitored by data safety committees with statisticians from groups like Biostatistics Collaboration. Key trials compared ipilimumab to chemotherapy or placebo, producing survival benefits that supported regulatory approvals by the FDA and EMA and coverage decisions by insurers and health technology assessment bodies including National Institute for Health and Care Excellence. Subsequent combination trials with PD‑1 inhibitors were conducted in registrational programs coordinated by consortia including ASCO trial networks and global clinical operations.

History and development

Discovery and early development trace to translational immunology work by investigators connected to institutions such as University of California, Berkeley, Yale University, and biotech startups that later partnered with Bristol Myers Squibb. Preclinical findings were advanced through collaborations with research institutes like the Howard Hughes Medical Institute and clinical translation took place in early phase units at Memorial Sloan Kettering Cancer Center and University of Pennsylvania. Regulatory milestones occurred in the 2010s following landmark publications in journals edited by boards including those of The New England Journal of Medicine and The Lancet, and recognition of immune checkpoint blockade transformed oncology practice parallel to other advances highlighted at conferences organized by ASCO and ESMO.

Category:Monoclonal antibodies